Neu­ro­crine's schiz­o­phre­nia da­ta are good enough for Phase 3 — but maybe not enough to beat Karuna

Neu­ro­crine Bio­sciences’ ef­fort to chase down Bris­tol My­ers Squibb and Karuna Ther­a­peu­tics in schiz­o­phre­nia just got more com­pli­cat­ed.

In a Phase 2 read­out Wednes­day morn­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER